ALRN Aileron Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

ALRN [NASD]

Aileron Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	1.20%	Shs Outstand	27.81M	Perf Week	-7.76%
Market Cap	39.76M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	-	Shs Float	25.34M	Perf Month	-14.40%
Income	-28.90M	PEG	-	EPS next Q	-0.19	Inst Own	12.90%	Short Float	3.77%	Perf Quarter	150.12%
Sales	-	P/S	-	EPS this Y	44.10%	Inst Trans	6.91%	Short Ratio	0.94	Perf Half Y	63.08%
Book/sh	0.35	P/B	3.06	EPS next Y	18.80%	ROA	-95.60%	Target Price	-	Perf Year	64.62%
Cash/sh	0.34	P/C	3.13	EPS next 5Y	2.10%	ROE	-147.10%	52W Range	0.25 - 1.99	Perf YTD	86.74%
Dividend	-	P/FCF	-	EPS past 5Y	-1.80%	ROI	-	52W High	-46.23%	Beta	-
Dividend %	-	Quick Ratio	2.20	Sales past 5Y	-	Gross Margin	-	52W Low	328.00%	ATR	0.11
Employees	13	Current Ratio	2.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.90	Volatility	7.64% 8.46%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	50.20%	Profit Margin	-	Rel Volume	0.75	Prev Close	1.12
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Apr 09 BMO	Payout	-	Avg Volume	1.02M	Price	1.07
Recom	1.40	SMA20	-8.08%	SMA50	9.22%	SMA200	63.27%	Volume	763,698	Change	-4.46%

Jul-24-17

Initiated

William Blair

Outperform

Jul-24-17

Initiated

Jefferies

Buy

$20

Jul-24-17

Initiated

BofA/Merrill

Buy

$19

Jun-29-20 08:30AM	Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan GlobeNewswire +7.27%
Jun-12-20 11:42AM	Largest Insider Trades of the Week GuruFocus.com
Jun-10-20 09:54AM	Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares GlobeNewswire +10.62%
Jun-04-20 09:15AM	Aileron Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -15.27%
Jun-03-20 04:01PM	Aileron Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +12.93%
Jun-02-20 10:22AM	The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics Zacks -21.09%
07:45AM	The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs Benzinga
Jun-01-20 08:34AM	5 Top Stocks Up 100%+ in May With More Room to Run Zacks -9.26%
07:00AM	Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer GlobeNewswire
May-27-20 08:30AM	Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent GlobeNewswire +5.91%
May-11-20 08:30AM	Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +6.81%
Apr-22-20 08:30AM	Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020 GlobeNewswire
Mar-30-20 04:16PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Dec-20-19 05:45PM	Hedge Fund Sentiment Is Unchanged On Aileron Therapeutics, Inc. (ALRN) Insider Monkey +11.08%
Dec-19-19 06:07AM	Are Insiders Buying Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock? Simply Wall St. +6.60%
Dec-18-19 08:30AM	Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer GlobeNewswire +8.16%
Nov-07-19 07:30AM	Aileron Therapeutics Reports Third Quarter 2019 Results GlobeNewswire -7.70%
Oct-31-19 08:30AM	Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th GlobeNewswire
Oct-29-19 08:00AM	Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference GlobeNewswire
Oct-21-19 08:00AM	Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th GlobeNewswire
Oct-16-19 08:30AM	Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent GlobeNewswire
Sep-28-19 07:30AM	Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizers Palbociclib at the 2019 Congress of the European Society for Medical Oncology GlobeNewswire
Sep-24-19 05:00PM	Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizers IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology GlobeNewswire -12.52%
Sep-19-19 07:24AM	How Much Money Does Aileron Therapeutics, Inc. (NASDAQ:ALRN) Have Left? Simply Wall St.
Sep-09-19 08:00AM	Aileron Therapeutics Announces Management Change GlobeNewswire
Sep-03-19 05:10PM	Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York GlobeNewswire
Aug-06-19 04:10PM	Aileron Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire
Jul-30-19 07:03PM	Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference GlobeNewswire -5.26%
04:47PM	Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019 GlobeNewswire
Jul-17-19 02:38PM	What Kind Of Shareholders Own Aileron Therapeutics, Inc. (NASDAQ:ALRN)? Simply Wall St.
Jun-27-19 08:00AM	Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy GlobeNewswire -5.26%
Jun-24-19 08:00AM	Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach GlobeNewswire
May-30-19 08:00AM	Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-08-19 04:57PM	Aileron Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
May-01-19 06:31PM	Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8 GlobeNewswire
Apr-03-19 12:15PM	Aileron Therapeutics Completes $26M Private Placement GlobeNewswire
Mar-29-19 09:00AM	Aileron Therapeutics Announces Pricing of $26M Private Placement GlobeNewswire
Mar-04-19 09:00AM	Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer GlobeNewswire
Feb-01-19 02:31PM	4 Healthcare Stocks Looking To Start February Off Strong ACCESSWIRE +29.09%
Jan-29-19 09:25AM	Aileron Therapeutics, Inc. (ALRN) Upgraded to Strong Buy: Here's Why Zacks
Jan-16-19 12:47PM	Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizers IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers GlobeNewswire +28.89%
Dec-21-18 11:33AM	Could The Aileron Therapeutics, Inc. (NASDAQ:ALRN) Ownership Structure Tell Us Something Useful? Simply Wall St. -13.92%
Dec-04-18 09:13AM	Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting GlobeNewswire -7.62%
Nov-28-18 10:22AM	Aileron Inks Collaboration Deal With Pfizer for Cancer Combo Zacks
Nov-27-18 08:00AM	Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers GlobeNewswire +9.84%
Nov-19-18 08:25AM	Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 04:10PM	Aileron Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 04:05PM	Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer GlobeNewswire
Nov-01-18 04:05PM	Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Childrens Cancer and Blood Disorders Center GlobeNewswire -10.64%
Oct-30-18 04:05PM	Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018 GlobeNewswire
Oct-19-18 08:00AM	Aileron Announces Poster Presentations at Two Scientific Conferences in November GlobeNewswire
Sep-06-18 09:00AM	Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer GlobeNewswire -11.26%
Aug-07-18 04:15PM	Aileron Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-02-18 07:00AM	Aileron Therapeutics to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jul-31-18 07:00AM	Aileron Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
May-29-18 07:00AM	Aileron Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-22-18 05:00AM	Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute GlobeNewswire
May-15-18 04:05PM	Aileron Therapeutics Announces Changes to Management GlobeNewswire
May-09-18 04:03PM	Aileron Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-11-18 04:05PM	Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia GlobeNewswire +11.04%
Apr-02-18 04:09PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-28-18 07:00AM	Aileron Therapeutics Announces Expansion of Scientific Advisory Board GlobeNewswire
Mar-19-18 07:00AM	Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors GlobeNewswire +7.18%
Dec-11-17 04:30PM	Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting GlobeNewswire
Nov-09-17 04:18PM	Aileron Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-01-17 09:19AM	Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting GlobeNewswire +9.55%
Oct-05-17 06:40AM	Boston biotech developing obesity drug pulls down $120M in IPO American City Business Journals
Sep-19-17 07:00AM	Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes GlobeNewswire
Aug-24-17 07:00AM	Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting GlobeNewswire
Aug-10-17 04:11PM	Aileron Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-03-17 07:00AM	Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference GlobeNewswire
Jul-19-17 09:21AM	[$$] Novartis, Glaxo and Lilly Bigly Back New Biotech Barrons.com
Jul-07-17 12:46PM	The Largest Insider Trades of the Week GuruFocus.com
Jul-03-17 01:02PM	Here's the Latest on Four New Biotech IPOs TheStreet.com
Jun-28-17 10:06PM	Aileron Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ambros Reinhard J.	Director	Jun 15	Buy	1.22	5,800	7,076	5,800	Jun 17 04:31 PM
Satter Muneer A	Director	Jun 08	Buy	1.10	3,700,000	4,070,000	7,609,449	Jun 09 08:22 PM
VON RICKENBACH JOSEF H	Director	Jun 08	Buy	1.10	227,272	249,999	445,460	Jun 09 08:23 PM
Bailey Jeffrey Allen	Director	Nov 15	Buy	0.51	39,142	19,962	74,894	Nov 18 04:15 PM
Bailey Jeffrey Allen	Director	Nov 14	Buy	0.51	15,858	8,088	35,752	Nov 18 04:15 PM
Bailey Jeffrey Allen	Director	Nov 12	Buy	0.53	19,894	10,544	19,894	Nov 14 04:23 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience